Latest Insider Transactions at Intellia Therapeutics, Inc. (NTLA)
This section provides a real-time view of insider transactions for Intellia Therapeutics, Inc. (NTLA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Intellia Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Intellia Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 04
2020
|
John M Leonard President and CEO |
SELL
Open market or private sale
|
Direct |
50,000
-9.66%
|
$1,300,000
$26.0 P/Share
|
|
Nov 04
2020
|
John M Leonard President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+8.81%
|
$300,000
$6.83 P/Share
|
|
Nov 04
2020
|
Jose E Rivera EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
3,364
-7.36%
|
$94,192
$28.0 P/Share
|
|
Nov 04
2020
|
Jose E Rivera EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+9.87%
|
$65,000
$13.88 P/Share
|
|
Oct 15
2020
|
Jose E Rivera EVP, General Counsel |
SELL
Open market or private sale
|
Direct |
5,615
-6.09%
|
$134,760
$24.37 P/Share
|
|
Oct 15
2020
|
Jose E Rivera EVP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+17.76%
|
$60,000
$6.83 P/Share
|
|
Oct 07
2020
|
John M Leonard President and CEO |
SELL
Open market or private sale
|
Direct |
5,000
-1.06%
|
$105,000
$21.83 P/Share
|
|
Oct 07
2020
|
John M Leonard President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.05%
|
$30,000
$6.83 P/Share
|
|
Dec 12
2017
|
Novartis Institutes For Bio Medical Research, Inc. > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,523,000
-26.94%
|
$27,414,000
$18.3 P/Share
|
|
Mar 03
2017
|
Novartis Institutes For Bio Medical Research, Inc. > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
79,245
+1.38%
|
-
|
|
May 11
2016
|
Novartis Institutes For Bio Medical Research, Inc. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
277,777
+4.75%
|
$4,999,986
$18.0 P/Share
|
|
May 11
2016
|
Novartis Institutes For Bio Medical Research, Inc. > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
5,295,881
+28.31%
|
-
|